{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:05:42Z","timestamp":1777878342666,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>\n                    Several clinical trials with anti-CD20 antibodies have successfully treated Acute Lymphoblastic Leukemia. Nevertheless, systematic comparisons between different anti-CD20 antibody trials are rare, and a comprehensive evaluation of their efficacy and safety has yet to be performed. The purpose of this systematic review and meta-analysis was to assess the efficacy and safety of anti-CD20 antibodies in the treatment of acute lymphoblastic leukemia and to guide clinical decision-making regarding the use of anti-CD20 antibody therapy. According to the PRISMA guidelines, Embase, Cochrane Library, PubMed, Web of Science, and ClinicalTrials.gov were searched for clinical trials conducted up to November 1, 2024, for the evaluation of anti-CD20 antibodies (rituximab, obinutuzumab, and ofatumumab) and corresponding controls. After screening the literature and extracting data, study quality was assessed using the Cochrane ROB 2 tool (RCTs) and the Newcastle-Ottawa Scale (cohorts). Heterogeneity was assessed using the I\u00b2 test. Based on the results of the heterogeneity test, meta-analysis was performed in RevMan 5.4 software with either a random-effects model or a fixed-effects model. We combined data from eight studies (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u20091330 patients, including two RCTs and six cohorts). Meta-analysis showed that anti-CD20 monoclonal antibodies significantly improved overall survival (OR\u2009=\u20091.89, 95% CI: 1.21\u20132.95,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.005) and event-free survival [OR\u2009=\u20091.68, 95% CI: 1.32\u20132.14,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u20090.0001] after &gt;1-year follow-up, and increased complete remission rates (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u20090.05). No significant differences were observed in common adverse events between groups. Subgroup analyses by study type did not alter these conclusions. Overall, anti-CD20 antibody therapy was more efficacious than the corresponding control and did not increase the incidence of grade 3\u20134 adverse events. Ofatumumab may be a more effective anti-CD20 antibody for the treatment of ALL.\n                  <\/jats:p>","DOI":"10.1177\/20406207251401313","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:27:53Z","timestamp":1766125673000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1027-1842","authenticated-orcid":false,"given":"Xiaomei","family":"Zhou","sequence":"first","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China"},{"name":"People\u2019s Liberation Army The General Hospital of Western Theater Command, Hematology, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxi","family":"Yang","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army The General Hospital of Western Theater Command, Hematology, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Fan","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army The General Hospital of Western Theater Command, Hematology, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xupai","family":"Zhang","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army The General Hospital of Western Theater Command, Hematology, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army The General Hospital of Western Theater Command, Hematology, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[{"name":"People\u2019s Liberation Army the General Hospital of Western Theater Command, Hematology, Chengdu, Sichuan 610083, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000245317.82391.1b"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29383"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1"},{"key":"e_1_3_4_5_2","first-page":"531","volume-title":"American Society of Hematology Self-Assessment Program","author":"Litzow MR","year":"2016","unstructured":"Litzow MR, Heyman M. Acute lymphoblastic leukemia and lymphoblastic lymphoma. In: American Society of Hematology Self-Assessment Program. 6th ed. The American Society of Hematology; 2016, pp. 531\u2013546.","edition":"6"},{"key":"e_1_3_4_6_2","first-page":"1556","volume-title":"Wintrobe\u2019s Clinical Hematology","author":"Steven CE","unstructured":"Steven CE. Acute lymphoblastic leukemia in adults. In: Greer JP, Arber DA, Glader B, et al. Wintrobe\u2019s Clinical Hematology, 13th ed. Philadelphia: Lippincott Williams & Wilkins, 2013: 1556\u20131576.","edition":"13"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.312"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0752-8"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3960"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016709"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010306"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.054064"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230"},{"key":"e_1_3_4_18_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_4_19_2","unstructured":"Wells GA Shea B O\u2019Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford 2000. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"e_1_3_4_20_2","first-page":"195","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori L","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implementation 2018; 16(4): 195\u2013203.","journal-title":"JBI Evid Implementation"},{"key":"e_1_3_4_21_2","article-title":"Core GRADE 2: choosing the target of certainty rating and assessing imprecision","volume":"389","author":"Guyatt G","year":"2025","unstructured":"Guyatt G, Zeng L, Brignardello-Petersen R, et al. Core GRADE 2: choosing the target of certainty rating and assessing imprecision. BMJ 2025; 389: e081904.","journal-title":"BMJ"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00038-2"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.02.013"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.008"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33655"},{"issue":"4","key":"e_1_3_4_28_2","first-page":"152","article-title":"Prognostic significance of CD20 expression in Adults B-cell acute lymphoblastic leukemia","volume":"18","author":"Shamki BA","year":"2023","unstructured":"Shamki BA, Naji AS, Alwan AF. Prognostic significance of CD20 expression in Adults B-cell acute lymphoblastic leukemia. Revista Latinoamericana De Hipertension 2023; 18(4): 152\u2013157.","journal-title":"Revista Latinoamericana De Hipertension"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-00945-7"},{"key":"e_1_3_4_30_2","article-title":"Mechanism of action of Rituximab","volume":"12","author":"Maloney DG.","year":"2001","unstructured":"Maloney DG. Mechanism of action of Rituximab. Anti-cancer Drugs 2001; 12: S1\u2013S4.","journal-title":"Anti-cancer Drugs"},{"issue":"1","key":"e_1_3_4_31_2","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow KU","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87(1): 33\u201343.","journal-title":"Haematologica"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.401"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01992-z"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(03)02714-4"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.27.9836"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129884"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000381524"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13764"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586610"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1"},{"key":"e_1_3_4_47_2","first-page":"1748","volume-title":"Clinical commissioning policy: addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) (P200901P)","author":"NHS England","year":"2021","unstructured":"NHS England. Clinical commissioning policy: addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) (P200901P). London: NHS England, 2021[2025-10-09]. URN: 1748."}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251401313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251401313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251401313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:04Z","timestamp":1777591084000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251401313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"alternative-id":["10.1177\/20406207251401313"],"URL":"https:\/\/doi.org\/10.1177\/20406207251401313","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20406207251401313"}}